Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cara Therapeutics (CARA)

Cara Therapeutics (CARA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cara: Q4 Earnings Snapshot

Cara: Q4 Earnings Snapshot

CARA : 0.7601 (+3.68%)
Mira Pharmaceuticals Stock Is Soaring In November... Here's Why

Leveraging a favorable DEA classification for its synthetic analog of THC, Mira Pharmaceuticals could be on an expedited pathway toward commercialization to treat several unmet neurological m

MIRA : 0.7500 (-1.30%)
CARA : 0.7601 (+3.68%)
CRBP : 43.74 (+3.18%)
HRMY : 31.28 (-1.32%)
JAZZ : 113.12 (+2.19%)
Cara: Q3 Earnings Snapshot

Cara: Q3 Earnings Snapshot

CARA : 0.7601 (+3.68%)
Cara: Q2 Earnings Snapshot

Cara: Q2 Earnings Snapshot

CARA : 0.7601 (+3.68%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/CNW/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute for...

CARA : 0.7601 (+3.68%)
Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

/PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that England's National Institute...

CARA : 0.7601 (+3.68%)
Cara: Q1 Earnings Snapshot

Cara: Q1 Earnings Snapshot

CARA : 0.7601 (+3.68%)
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 10% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DARE : 0.3136 (+2.12%)
CARA : 0.7601 (+3.68%)
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 16.67% and 20.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SCPH : 4.81 (+2.56%)
CARA : 0.7601 (+3.68%)
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of -0.66% and 37.92%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RGNX : 15.68 (-5.94%)
CARA : 0.7601 (+3.68%)

Barchart Exclusives

Stock Index Futures Climb as Fed Rate Cut Hopes Grow, Fed Speak and ECB Minutes in Focus
June S&P 500 E-Mini futures (ESM24) are up +0.40%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.44% this morning after three major U.S. benchmark indices ended the regular session in the green as higher-than-expected applications for U.S. unemployment benefits bolstered the case for rate cuts, with investors looking ahead to fresh comments from Federal Reserve officials. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar